| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 1893 | 2018 |
| Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ... Annals of Oncology 29 (8), 1853-1860, 2018 | 375 | 2018 |
| Implications of the tumor immune microenvironment for staging and therapeutics JM Taube, J Galon, LM Sholl, SJ Rodig, TR Cottrell, NA Giraldo, AS Baras, ... Modern Pathology 31 (2), 214-234, 2018 | 331 | 2018 |
| Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ... Nature 596 (7870), 126-132, 2021 | 277 | 2021 |
| Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ... Cancer research 79 (6), 1214-1225, 2019 | 257 | 2019 |
| RNA Interference in the Pathogenic Fungus Cryptococcus neoformans H Liu, TR Cottrell, LM Pierini, WE Goldman, TL Doering Genetics 160 (2), 463-470, 2002 | 241 | 2002 |
| Melanoma subtypes demonstrate distinct PD-L1 expression profiles GJ Kaunitz, TR Cottrell, M Lilo, V Muthappan, J Esandrio, S Berry, H Xu, ... Laboratory investigation 97 (9), 1063-1071, 2017 | 178 | 2017 |
| Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors L Danilova, H Wang, J Sunshine, GJ Kaunitz, TR Cottrell, H Xu, ... Proceedings of the National Academy of Sciences 113 (48), E7769-E7777, 2016 | 178 | 2016 |
| Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab NA Giraldo, P Nguyen, EL Engle, GJ Kaunitz, TR Cottrell, S Berry, ... Journal for immunotherapy of cancer 6, 1-11, 2018 | 147 | 2018 |
| Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade S Berry, NA Giraldo, BF Green, TR Cottrell, JE Stein, EL Engle, H Xu, ... Science 372 (6547), eaba2609, 2021 | 134 | 2021 |
| PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison JC Sunshine, PL Nguyen, GJ Kaunitz, TR Cottrell, S Berry, J Esandrio, ... Clinical Cancer Research 23 (16), 4938-4944, 2017 | 134 | 2017 |
| Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer JE Reuss, V Anagnostou, TR Cottrell, KN Smith, F Verde, M Zahurak, ... Journal for immunotherapy of cancer 8 (2), 2020 | 131 | 2020 |
| PD-L1 and emerging biomarkers in immune checkpoint blockade therapy TR Cottrell, JM Taube The Cancer Journal 24 (1), 41-46, 2018 | 119 | 2018 |
| Silence of the strands: RNA interference in eukaryotic pathogens TR Cottrell, TL Doering TRENDS in Microbiology 11 (1), 37-43, 2003 | 119 | 2003 |
| Pan-tumor pathologic scoring of response to PD-(L) 1 blockade JE Stein, EJ Lipson, TR Cottrell, PM Forde, RA Anders, ... Clinical Cancer Research 26 (3), 545-551, 2020 | 106 | 2020 |
| Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non–small cell lung cancer J Zhang, Z Ji, JX Caushi, M El Asmar, V Anagnostou, TR Cottrell, ... Clinical Cancer Research 26 (6), 1327-1337, 2020 | 105 | 2020 |
| Transcriptional mechanisms of resistance to anti–PD-1 therapy ML Ascierto, A Makohon-Moore, EJ Lipson, JM Taube, TL McMiller, ... Clinical cancer research 23 (12), 3168-3180, 2017 | 80 | 2017 |
| Chronic immune checkpoint inhibitor pneumonitis J Naidoo, TR Cottrell, EJ Lipson, PM Forde, PB Illei, LB Yarmus, ... Journal for immunotherapy of cancer 8 (1), 2020 | 72 | 2020 |
| Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy EL Yanik, GJ Kaunitz, TR Cottrell, F Succaria, TL McMiller, ML Ascierto, ... JAMA oncology 3 (7), 974-978, 2017 | 70 | 2017 |
| The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis TR Cottrell, RA Wise, FM Wigley, F Boin Annals of the rheumatic diseases 73 (6), 1060-1066, 2014 | 54 | 2014 |
